所有图片(1)
About This Item
经验公式（希尔记法）:
C19H20N2O2
CAS号:
分子量:
308.37
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
phenylbutazone
製造商／商標名
EDQM
mp
106-108 °C (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CCCCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3
InChI
1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
InChI 密鑰
VYMDGNCVAMGZFE-UHFFFAOYSA-N
基因資訊
human ... PTGS1(5742) , PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Phenylbutazone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
J Aarbakke
Clinical pharmacokinetics, 3(5), 369-380 (1978-09-01)
More than 25 years after phenylbutazone was introduced as a non-steroidal anti-inflammatory agent, basic knowledge is still accumulating on its pharmacokinetics in man. Phenylbutazone is almost completely absorbed after oral administration. A large fraction of the drug in plasma is
Robert D Combes
Alternatives to laboratory animals : ATLA, 41(3), 235-248 (2013-08-27)
Published in silico, in vitro, in vivo laboratory animal and human data, together with information on biotransformation and data from structure-activity analyses with two decision-tree systems (ACToR and Toxtree), have been used in a weight-of-evidence (WoE) assessment to determine whether
T Tobin et al.
Journal of veterinary pharmacology and therapeutics, 9(1), 1-25 (1986-03-01)
Phenylbutazone is an acidic, lipophilic, non-steroidal anti-inflammatory drug (NSAID). It is extensively metabolized in the horse. The metabolites so far identified, oxyphenbutazone, gamma-hydroxyoxyphenbutazone, account for some 25-30% of administered dose over 24 h. The plasma half-life of phenylbutazone and termination
[Multiple manifestations of intolerance in association with anti-inflammatory agents. Role of phenylbutazone].
F Tolot et al.
Semaine des hopitaux. Therapeutique, 52(3), 185-190 (1976-03-01)
M Maciazek-Jurczyk et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 74(1), 1-9 (2009-07-21)
The monitoring of drug concentration in blood serum is necessary in multi-drug therapy. Mechanism of drug binding with serum albumin (SA) is one of the most important factors which determine drug concentration and its transport to the destination tissues. In
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门